NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Eli Lilly and Company
Inspirna, Inc.
Huabo Biopharm Co., Ltd.
GOG Foundation
Eli Lilly and Company
SCRI Development Innovations, LLC